? ? The New England Node consists of its RRTC, the Division of Substance Abuse of the Yale University Department of Psychiatry in collaboration with Advanced Behavioral Health (ABH), a statewide network of substance abuse and mental health treatment providers, and its component CTPs (5 core, 7 ancillary). In the past 5 years we have met all of our original specific aims in establishing a research infrastructure in New England, effectively and efficiently leading and participating in multiple protocols, playing a major leadership role in the CTN at all levels and having made major contributions to the success of the CTN. Our unique contributions to the CTN during this period include: ? - Establishing a hybrid model of effectiveness research that has been adopted across CTN protocols ? - Providing extensive, effective leadership of the CTN with leadership of multiple protocols, ? - Developing strong synergy and greatly expanding the scope of clinical drug abuse research within our region, leading directly to 14 new funded research projects being conducted within our CTPs, ? - Sharing our expertise and serving as a resource in behavioral therapies development and clinical efficacy research broadly throughout the CTN, ? - Serving as a major source of protocol concepts and ideas through linkages with Yale investigators and our multiple clinical research centers and ? - Greatly enhancing the productivity and impact of the CTN by publishing over 40 papers on CTN research, as well as making over 50 presentations on the CTN at local, national, and international meetings. During the proposed renewal period, the specific aims of this project are to maintain and expand a highly successful infrastructure for drug abuse treatment research through the existing partnership of the Yale Division of Substance Abuse and a network of community treatment programs in New England in order to: ? - continue to conduct and support rigorous multisite clinical trials in community based clinical programs in a number of areas, including pharmacologic, behavioral, combined pharmacologic/behavioral, and related research to improve the quality of drug abuse treatment in the United States ? - expand the capacity of our Node and the CTN to rapidly respond to emerging issues in drug abuse as well as the CTN's capability to address new areas, including genetics, HIV, and comorbidity. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10DA013038-07
Application #
7119579
Study Section
Special Emphasis Panel (ZDA1-MXG-S (02))
Program Officer
Levy, Janet
Project Start
1999-09-30
Project End
2010-08-31
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
7
Fiscal Year
2006
Total Cost
$1,250,000
Indirect Cost
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Zhu, Yuhui; Evans, Elizabeth A; Mooney, Larissa J et al. (2018) Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol 13:488-497
Decker, Suzanne E; Morie, Kristen P; Malin-Mayo, Bo et al. (2018) Positive and negative affect in cocaine use disorder treatment: Change across time and relevance to treatment outcome. Am J Addict :
Crist, R C; Doyle, G A; Nelson, E C et al. (2018) A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J 18:173-179
Crist, Richard C; Li, James; Doyle, Glenn A et al. (2018) Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. Am J Drug Alcohol Abuse 44:431-440
Hser, Yih-Ing; Huang, David; Saxon, Andrew J et al. (2017) Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine?+?Naloxone and Methadone. J Addict Med 11:63-69
Pan, Yue; Liu, Hongmei; Metsch, Lisa R et al. (2017) Factors Associated with HIV Testing Among Participants from Substance Use Disorder Treatment Programs in the US: A Machine Learning Approach. AIDS Behav 21:534-546
Hser, Yih-Ing; Evans, Elizabeth; Huang, David et al. (2016) Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction 111:695-705
Hernández, Diana; Feaster, Daniel J; Gooden, Lauren et al. (2016) Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients. AIDS Behav 20:204-14
Gooden, Lauren; Metsch, Lisa R; Pereyra, Margaret R et al. (2016) Examining the Efficacy of HIV Risk-Reduction Counseling on the Sexual Risk Behaviors of a National Sample of Drug Abuse Treatment Clients: Analysis of Subgroups. AIDS Behav 20:1893-906
Serafini, Kelly; Decker, Suzanne; Kiluk, Brian D et al. (2015) Outcome expectations and associated treatment outcomes in motivational enhancement therapy delivered in English and Spanish. Am J Addict 24:732-9

Showing the most recent 10 out of 92 publications